Abstract
Background Drug-induced QTc prolongation (diQTP) is frequent and associated with a risk of sudden cardiac death. Identifying patients at risk of diQTP can enhance monitoring and treatment plans.
Objective To develop a machine learning architecture for prediction of extreme diQTP (QTc >500ms OR ΔQTc >60ms) at the onset of treatment with a QTc prolonging drug.
Methods We included 4,628 adult patients who received a baseline ECG within 6 months prior to treatment onset with a QTc prolonging drug and a follow-up ECG after the fifth dose. We collected known clinical QTc prolongation risk factors (CF). We developed a novel neural network architecture (QTNet) to predict diQTP from both the CF and baseline ECG data (ECGD), composed of both the ECG waveform and measurements (i.e. QTc),by fusing a state-of-the-art convolution neural network to process raw ECG waveforms with the CF using amulti-layer perceptron. We fit a logistic regression model using the CF, replicating RISQ-PATH as Baseline. We further compared the performance of QTNet (CF+ECGD) to neural network models trained using three variable subsets: a) baseline QTc (QTC-NN), b) CF-NN, and c) ECGD-NN.
Results diQTP was present in 1030 patients (22.3%), of which baseline QTc was normal (QTc<450ms:Male/<470ms:Female) in 405 patients (39.3%). QTNet achieved the best performance (Figure 1)(AUROC, 0.802 [95% CI, 0.782-0.820]), outperforming predictions based on the Baseline (AUROC, 0.738 [95%CI, 0.716-0.757]), QTC-NN (AUROC, 0.735 [95% CI, 0.710-0.757]), CF-NN (AUROC, 0.778 [95% CI, 0.757-0.799]), and ECGD-NN (AUROC, 0.774 [95% CI, 0.750-0.794]).
Conclusion We developed QTNet, the first deep learning model for predicting extreme diQTP, outperforming models trained on known clinical risk factors.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
none
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
NYU Langone Health IRB
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data will not be available due to PHI inclusion
